Several studies have addressed the prognostic and predictive value of the methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) gene in patients with glioblastoma multiforme (GBM). In a translational study analyzing the randomized EORTC-26981-22981/ NCIC-CE3 trial by Stupp et al. [9] , Hegi and coworkers [4] first demonstrated that the benefit of combined radiotherapy and temozolomide chemotherapy over radiotherapy alone was significant in GBM patients with a methylated MG-MT promoter (median survival: 21.7 versus 15.3 months; p<0.001), but only slight and borderline significant in those with an unmethylated status (median survival: 12.7 versus 11.8 months; p<0.06). MGMT promoter methylation was found to be an independent prognostic factor for survival (hazard ratio: 0.41; p=0.001). However, these initial results were partly offset by the results of a five-year analysis published by the same group at a later date [8] . In the latter study, the addition of temozolomide to radiotherapy also had a significant beneficial effect in patients with an unmethylated MGMT promoter (median survival: 12.6 vs. 11.8 months; p=0.035).
The predictive value of MGMT promoter methylation status was also demonstrated in two recent studies on the treatment of elderly GBM patients over 65 [11] and 60 years of age [5] : in the groups treated with temozolomide alone, patients with a methylated MGMT promoter had a better prognosis than those without methylation. Within these groups, the NOA-08 trial [11] showed an advantage in terms of event-free survival (median: 8.4 versus 3.3 months; p=0.01), while the Nordic study by Malmstrom et al. [5] demonstrated an additional benefit in terms of overall survival (median: 9.7 vs. 6.8 months; p=0.02). Conversely, MGMT promoter methylation status had no impact among patients treated with radiotherapy alone.
Consequently, there are now frequent demands for the routine use of MGMT promoter methylation as a predictive and prognostic factor in clinical practice. For example, Platten and colleagues [6] stated that the decision to forego radio-or chemotherapy should depend on the methylation status of the MGMT gene. For individuals over 65 years of age, this means that temozolomide chemotherapy alone should be administered in patients with a methylated MGMT promoter and radiotherapy alone in those with an unmethylated MGMT promoter. Nowadays, more and more studies are being designed for the exclusive inclusion of patients with a specific MGMT status (compare the CENTRIC, CeTeG and Glarius studies). This assumes a widespread availability of standardized, reliable and validated methods for the determination of MGMT promoter methylation status.
However, we would like to point out that there are still many uncertainties associated with the practical implementation of MGMT promoter methylation analysis. In our view, it would be premature to use the MGMT status as a biomarker for treatment selection in routine clinical practice at this stage. Our opinion is supported by a recent review published by Berghoff and colleagues in Austria [1] .
What are the current arguments against the routine use of MGMT promoter methylation status in clinical practice? F Various methods for the determination of MGMT promoter methylation status have been developed and are currently available. However, sufficient evidence demonstrating the intra-and interlaboratory reproducibility of any of these tests is still lacking. Therefore, in their clinical neuropathology practice guide, Berghoff et al. demand a scientific analysis of the reproducibility of these tests, stating"This lack of evidence impedes recommendation of MGMT testing for routine clinical use" [1] . F The MGMT gene promoter contains a total of 97 potential CpG methylation sites. However, it is frequently the case that only a small sample (5 to 9) of these sites are analyzed, depending on the analytical method used. The methylation patterns show some heterogeneity between different patients, but there is evidence that the prognostic significance of the individual methylation sites differ [7] . Consequently, the prognostic and predictive value of MGMT status must always be interpreted in terms of the particular method used and the specific methylation sites assessed. In our opinion, it is therefore problematic to transfer the significance of the MGMT status as defined in the aforementioned studies to alternative methods or different methylation sites in an uncritical manner. The different methods and CpG sites studied in the cited publications are listed in . Tab. 1. F The previously published studies of MGMT promoter methylation status set high standards for the sample materials used for analysis. In the NOA-08 study, for example, only those tissue samples with a tumor cell content of at least 80% were accepted for analy sis [11] . In our experience, this restricts the possibility of determining the MGMT status in practice to just 40 to 60% of all GBM patients. The tumor cell content of the remaining samples will be too low to ensure the reliable determination of MGMT promoter methylation status under the present conditions. Currently available studies show similarly low rates of analysis (. Tab. 1). Furthermore, the two studies with a 100% success rate used frozen tissue sections, which are not always available in routine practice. This means that, in clinical practice, the MGMT promoter methylation status cannot be determined in a significant proportion of patients due to a lack of suitable sample material. F In the EORTC-26981-22981/NCIC-CE3 study [9] , the addition of temozolomide to radiotherapy resulted in a small, yet statistically significant survival benefit for GBM patients with an unmethylated MGMT status. This implies that MGMT-negative GBM patients might also benefit from temozolomide. CpG sites as defined by Shah et al. [7] . GBM glioblastoma, AA anaplastic astrocytoma, NA not available.
2005 study). On the other hand, the studies by Wick et al. [11] and Malmström et al. [5] provided evidence demonstrating the predictive value of MGMT status in elderly patients treated with temozolomide alone, whereas the effect of radiotherapy was independent of the MGMT status. Combined treatment with temozolomide and radiotherapy has not yet been tested in this age group. In our opinion, it is therefore not possible to draw reliable conclusions regarding the treatment of elderly GBM patients using this approach.
Taken together, these arguments suggest that: F MGMT promoter methylation status cannot be reliably determined at all routine laboratories at the present time. F It is unclear which method and which tumor material should or could be used. F It is unclear which methylation sites allow a reliable predictive and/or prognostic assessment. F There are still too few independent studies on the prognostic and predictive value of MGMT promoter gene methylation to permit its use in treatment decisions relating to the use of combined radiotherapy and chemotherapy in elderly GBM patients.
Therefore, it is imperative that well-defined and reproducible conditions for the determination of MGMT promoter methylation status are established prior to the introduction of MGMT status in routine diagnostics and daily clinical practice (e.g., when making treatment decisions for older GBM patients). From a radio-oncological perspective, it is necessary to clearly identify the treatment regimens (e.g., combined radiotherapy and chemotherapy) in which MGMT status is really significant.
We are confident that MGMT status can play an important role in individualized treatment planning for GBM in the future. However, its precise role remains to be clarified in further studies. At present, routine use of MGMT status should be exercised with extreme caution as it is subject to the aforementioned limitations and difficulties associated with the interpretation of the results.
